Search Patents
  • Methods for characterizing loss of antigen presentation
    Patent number: 11920194
    Abstract: This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: March 5, 2024
    Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Ugur Sahin, Martin Suchan, Barbara Schrörs, Martin Löwer, Petra Oehm
  • RNA for treatment of autoimmune diseases
    Patent number: 11701413
    Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: July 18, 2023
    Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Sebastian Kreiter, Christina Krienke, Jutta Petschenka, Lena Mareen Kranz, Mustafa Diken
  • Cytokine Fusion Proteins
    Publication number: 20190276511
    Abstract: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
    Type: Application
    Filed: April 3, 2019
    Publication date: September 12, 2019
    Inventors: Ugur Sahin, Friederike Gieseke, Ronald Backer, Sebastian Kreiter, Roland Kontermann, Klaus Pfizenmaier, Sina Fellermaier, Dafne Müller
  • LOCALIZED ADMINISTRATION OF RNA MOLECULES FOR THERAPY
    Publication number: 20220062439
    Abstract: The present invention relates to local delivery to an organ and/or tissue of an agent such as a peptide and/or polypeptide, by administration of an RNA molecule encoding such agent to an afferent blood vessel of the organ and/or tissue. The agent is thus able to provide its biological function, e.g., therapeutic effect, locally and avoid unwanted systemic effects, including any toxicity observed when the agent encoded by the RNA and/or the encoding RNA itself is administered systemically.
    Type: Application
    Filed: January 9, 2020
    Publication date: March 3, 2022
    Inventor: Ugur Sahin
  • BINDING AGENTS BINDING TO EPCAM AND CD137
    Publication number: 20230295335
    Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
    Type: Application
    Filed: March 15, 2023
    Publication date: September 21, 2023
    Inventors: Andreea IOAN, Esther Cornelia Wilhelmina BREIJ, Lars GUELEN, David P.E. SATIJN, Ugur SAHIN, Alexander MUIK, Kristina SCHÖDEL, Sina FELLERMEIER-KOPF, Bart-Jan DE KREUK, Richard HIBBERT, Janine SCHUURMAN, Aran Frank LABRIJN
  • Tumor antigens for determining cancer therapy
    Patent number: 11628209
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 18, 2023
    Assignees: Tron GGMBH, BioNTech SE
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS
    Publication number: 20180073077
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 15, 2018
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
  • RNA constructs and uses thereof
    Patent number: 11779659
    Abstract: Disclosed herein are RNA polynucleotides comprising a 5? Cap, a 5? UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: October 10, 2023
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Gábor Boros, Azita Josefine Mahiny, Jonas Reinholz, Katalin Karikó
  • Recombinant vaccines and use thereof
    Patent number: 8637006
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 28, 2014
    Assignee: BioNTech AG
    Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
  • Genetic products differentially expressed in tumors and use thereof
    Publication number: 20060013817
    Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
    Type: Application
    Filed: March 12, 2003
    Publication date: January 19, 2006
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
  • Antibodies against claudin 18.2 useful in cancer diagnosis
    Patent number: 11976130
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: May 7, 2024
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
  • GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF
    Publication number: 20160002738
    Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 7, 2016
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Recombinant vaccines and use thereof
    Patent number: 8178653
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the transmembrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: May 15, 2012
    Assignee: BioNTech AG
    Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
  • GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF
    Publication number: 20170101479
    Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
    Type: Application
    Filed: September 22, 2016
    Publication date: April 13, 2017
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Identification of Tumor-Associated Antigens for Diagnosis and Therapy
    Publication number: 20090202530
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Application
    Filed: September 6, 2006
    Publication date: August 13, 2009
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Dirk Usener
  • PREDICTING IMMUNOGENICITY OF T CELL EPITOPES
    Publication number: 20160125129
    Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
    Type: Application
    Filed: May 7, 2014
    Publication date: May 5, 2016
    Applicants: BioNTech AG, TROM
    Inventors: Ugur Sahin, Arbel David Tadmor, John Christopher Castle, Sebastian Boegel, Martin Löwer
  • Antigen receptors and uses thereof
    Patent number: 11702631
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 18, 2023
    Inventors: Ralf Holger Voss, Ugur Sahin, Petra Oehm, Matthias Birtel, Janina Caspar
  • Identification of surface-associated antigens for tumor diagnosis and therapy
    Patent number: 10302647
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: May 28, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
  • GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF
    Publication number: 20170240646
    Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.
    Type: Application
    Filed: March 3, 2017
    Publication date: August 24, 2017
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Koslowski, Stefan Fritz, Harald-Gerhard Geppert
  • Genetic Products Differentially Expressed In Tumors And The Use Thereof
    Publication number: 20140186338
    Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Application
    Filed: October 1, 2013
    Publication date: July 3, 2014
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
Narrow Results

Filter by US Classification